How does AICAR compare to SLU-PP-332?

Both are exercise mimetics but target different pathways. AICAR activates AMPK (the energy sensor that detects low cellular energy). SLU-PP-332 activates ERRs (nuclear receptors that control mitochondrial gene expression). AICAR increases endurance by 44% but requires injection and has significant off-target effects. SLU-PP-332 is more targeted but earlier in development. They likely have complementary rather than redundant effects.

Is AICAR banned in sports?

Yes. WADA added AICAR to its Prohibited List in 2009 under category S4 (Hormone and Metabolic Modulators). It was one of the first exercise mimetics to be explicitly banned, triggered by concerns about use in professional cycling.

Can AICAR replace exercise?

In mice, AICAR replicated some exercise benefits — increased endurance, oxidative muscle fibers, fat oxidation — but it activates only one pathway (AMPK) while exercise activates hundreds. It also has AMPK-independent effects that may include risks like neurodegeneration at high doses. It's best understood as a research tool, not an exercise substitute.

AICAR

The original 'exercise in a pill' — an AMPK activator that increased running endurance by 44% in sedentary mice. Banned by WADA since 2009. Studied for metabolic syndrome, diabetes, and cardioprotection.

ModerateLimited Data

What is AICAR?

AICAR (5-aminoimidazole-4-carboxamide ribonucleoside, also known as acadesine) is a cell-permeable nucleoside analog that activates AMP-activated protein kinase (AMPK), the master metabolic sensor that the body normally activates during exercise. In a landmark 2008 study published alongside the PPARδ agonist GW1516, AICAR increased running endurance by 44% in completely sedentary mice — without any training. This made it the first pharmacological "exercise mimetic" and triggered immediate doping concerns. WADA banned it in 2009, and the French anti-doping agency raised concerns about its use during the Tour de France. AICAR is not a peptide — it's a nucleoside analog — but it occupies a central position in exercise mimetic and metabolic optimization research, with connections to SLU-PP-332, MOTS-c, and other compounds in the endurance enhancement space.

Why People Talk About It

Exercise endurance enhancement without training (44% in mice)

Moderate

Metabolic syndrome and insulin sensitivity

Moderate

Fat oxidation and body composition

Moderate

Diabetic neuropathy prevention and reversal

Preliminary

Cardioprotection during ischemia

Moderate

How It Works

When you exercise, your cells burn ATP for energy, and AMP levels rise. AMPK detects this rising AMP and activates programs that burn fat, make new mitochondria, and improve endurance. AICAR bypasses the need for actual exercise — it gets converted into ZMP inside cells, which directly activates AMPK as if you'd just worked out. Your muscles respond by building more oxidative (endurance) fibers and burning more fat.

Common Questions

Safety Information

Important Safety Notes

Common Side Effects

Limited human safety data outside of cardioprotection trialsHypoglycemia risk (enhances insulin sensitivity and glucose uptake)Potential lactic acidosis at high doses

Cautions

• Banned by WADA — prohibited in all competitive sports
• Many AICAR effects previously attributed to AMPK are actually AMPK-independent — unpredictable off-target actions
• Excessive AMPK activation in wrong tissues may cause neurodegeneration or impair cell division
• Requires injection (poor oral bioavailability) — impractical for chronic use
• Not FDA-approved for any metabolic or performance indication

What We Don't Know

Long-term safety of chronic AMPK activation in humans is poorly understood. AICAR has significant AMPK-independent effects that are still being catalogued. Whether the endurance benefits seen in sedentary mice translate to trained humans is unknown. The therapeutic window between beneficial metabolic effects and adverse effects is not well-defined.

Published Research

6 studies

Administration of AICAR, an AMPK Activator, Prevents and Reverses Diabetic Polyneuropathy (DPN) by Regulating Mitophagy.

PreclinicalPMID: 39795939

Exercise in a Pill: The Latest on Exercise-Mimetics.

ReviewPMID: 29765854

Pharmacological targeting of exercise adaptations in skeletal muscle: Benefits and pitfalls.

ReviewPMID: 29061342

AMPK and PPARδ Agonists Are Exercise Mimetics.

Preclinical

AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review.

Systematic Review

Sustained AMPK activation improves muscle function in a mitochondrial myopathy mouse model.

Preclinical

Mechanism of Action

AICAR is a cell-permeable nucleoside that enters cells via adenosine transporters and is phosphorylated by adenosine kinase to ZMP (5-aminoimidazole-4-carboxamide ribotide), an AMP analog that allosterically activates AMPK. Activated AMPK phosphorylates multiple downstream targets: ACC (increasing fatty acid oxidation), PGC-1α (stimulating mitochondrial biogenesis), GLUT4 (enhancing glucose uptake), and TSC2 (inhibiting mTOR-dependent anabolic pathways). In skeletal muscle, 4 weeks of AICAR treatment (500 mg/kg/day IP) induced 32 oxidative metabolism genes, increased type I (slow-twitch) fatigue-resistant muscle fibers, enhanced running distance by 44%, and decreased epididymal fat mass — all in sedentary mice with no exercise. The transcriptional program required PPARδ: AICAR failed to induce oxidative gene expression in PPARδ-null cells. However, a systematic review identified numerous AMPK-independent AICAR effects, complicating interpretation of earlier studies that attributed all effects to AMPK activation.

Evidence Snapshot

Overall Confidence50%

Human Clinical Evidence

Limited for exercise/metabolic indications. AICAR (acadesine) was tested in Phase 2/3 human trials for cardioprotection during coronary artery bypass surgery, showing reduced early cardiac death and MI. No human trials for exercise performance or obesity have been published. WADA prohibition makes human performance studies ethically and legally complex.

Animal / Preclinical

Strong. The foundational Cell paper (2008) demonstrated 44% endurance increase in sedentary mice with muscle fiber type shifts and fat mass reduction. Subsequently validated across multiple metabolic models: improved insulin sensitivity, diabetic polyneuropathy prevention (2024), mitochondrial myopathy improvement, and obesity protection. The AMPK-independent effects systematic review (2021) identified important caveats.

Mechanistic Rationale

Strong for AMPK pathway but complicated. AMPK's role in exercise adaptation is well-validated. AICAR's conversion to ZMP and allosteric AMPK activation is well-characterized. However, AICAR has significant AMPK-independent effects, and the PPARδ dependency of its exercise-mimetic effects adds complexity. Excessive AMPK activation carries real risks.

Forms & Administration

AICAR has been administered via intraperitoneal injection in animal studies (250-500 mg/kg/day) and intravenous infusion in human cardioprotection trials. It has poor oral bioavailability. It is not available through legitimate medical channels for performance or metabolic use. Banned by WADA.

Use Cases & Evidence Levels

Exercise endurance enhancement without training (44% in mice)

Moderate70%

Metabolic syndrome and insulin sensitivity

Moderate70%

Fat oxidation and body composition

Moderate70%

Diabetic neuropathy prevention and reversal

Preliminary30%

Cardioprotection during ischemia

Moderate70%

Safety Profile

Safety Information

Common Side Effects

Limited human safety data outside of cardioprotection trialsHypoglycemia risk (enhances insulin sensitivity and glucose uptake)Potential lactic acidosis at high doses

Cautions

• Banned by WADA — prohibited in all competitive sports
• Many AICAR effects previously attributed to AMPK are actually AMPK-independent — unpredictable off-target actions
• Excessive AMPK activation in wrong tissues may cause neurodegeneration or impair cell division
• Requires injection (poor oral bioavailability) — impractical for chronic use
• Not FDA-approved for any metabolic or performance indication

What We Don't Know

Published Research

6 studies

Administration of AICAR, an AMPK Activator, Prevents and Reverses Diabetic Polyneuropathy (DPN) by Regulating Mitophagy.

PreclinicalPMID: 39795939

Exercise in a Pill: The Latest on Exercise-Mimetics.

ReviewPMID: 29765854

Pharmacological targeting of exercise adaptations in skeletal muscle: Benefits and pitfalls.

ReviewPMID: 29061342

AMPK and PPARδ Agonists Are Exercise Mimetics.

Preclinical

AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review.

Systematic Review

Sustained AMPK activation improves muscle function in a mitochondrial myopathy mouse model.

Preclinical

Related Peptides

SLU-PP-332

Preliminary

A synthetic exercise mimetic that activates estrogen-related receptors (ERRs) to replicate the molecular effects of aerobic exercise — increasing endurance, fat oxidation, and mitochondrial function without physical activity.

MOTS-c

Emerging

A mitochondria-derived peptide that regulates metabolic homeostasis and has been called an 'exercise mimetic.'

SS-31

Emerging

A mitochondria-targeted peptide in clinical trials for heart failure and mitochondrial diseases.

Humanin

Emerging

A mitochondria-derived peptide with cytoprotective properties, studied for neuroprotection, metabolic regulation, and anti-aging effects.

5-Amino-1MQ

Preliminary

A selective NNMT inhibitor that reduces fat mass by boosting NAD+ and cellular energy expenditure — without affecting appetite. In mice, 11 days of treatment produced 5% weight loss and 35% reduction in white adipose tissue.

Quick Facts

Class: Exercise Mimetic
Evidence: Moderate
Safety: Limited Data
Updated: Apr 2026
Citations: 6PubMed

Also known as

Acadesine5-Aminoimidazole-4-Carboxamide RibonucleosideAICArZMP Precursor

Evidence Score

Overall Confidence50%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.